Lupin Gets FDA Ok for Generic Psoriasis Treatment

Dec 28, 2017

Mumbai-based Lupin announced it has received final approval from the U.S. FDA for its generic version of Lep Pharmaceutical Products’ Dovonex scalp solution.

Lupin's calcipotriene topical treatment is used to treat chronic, moderately severe psoriasis of the scalp.  

According to the company, Lupin is the 8th largest generics pharmaceutical company by market capitalization and 6th largest generics pharmaceutical company by revenues.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments